Biological agents for the treatment of uveitis

Expert Opinion on Biological Therapy

Volumn 12, Issue 3, 2012, Pages 311-328

  Servat, Juan Javier ^a   Mears, Katrina A ^b   Black, Evan H ^b   Huang, John J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Biologics; Cytokines; Interferons; Interleukin blocker; Intravenous immunoglobulin; Ocular inflammation; Tumor necrosis factor; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ALPHA INTERFERON; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

BEHCET DISEASE; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; EYE INFLAMMATION; HUMAN; INFECTION RISK; NAUSEA AND VOMITING; NONHUMAN; PEER REVIEW; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UVEITIS; VOGT KOYANAGI SYNDROME;

BIOLOGICAL AGENTS; HUMANS; UVEITIS;

EID: 84863116481     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.658366     Document Type: Review

References (173)

1. Havener WA. Ocular Pharmacology. St. Louis: C.V. Mosby; 1983. p. 475-91
2. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-14 (Pubitemid 43170781)
3. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9 (Pubitemid 30151920)
4. Hertz R. Folic Acid Antagonist. Effects on the cell and the patient. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1963;59:931-56
5. Foster CS, Vitale AT. Diagnosis and treatment of uveitis. Sauders; Philadelphia: 2002. p. 177-214
6. Borel JF. The History of cyclosporine A and its significance. In: White DJG, editor. Cyclosporine A. Elsevier Biomedical Press; New York 5-17
7. Whitcup SM, Hikita N, Shirao M, et al. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res 1995;60:597-601
8. Ahmadi-Simab K, Lamprecht P, Nolle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogrens syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8 (Pubitemid 40909530)
9. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110:1061-5 (Pubitemid 36560514)
10. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63(3):395-400 (Pubitemid 351499869)
11. Hauser SL, Waubant E, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88 (Pubitemid 351240747)
12. Elsching A. Studien zur sympathischen ophthalmic. Die antigene wirkung des augenpigmentes. Graefes Arch Ophthalmol 1910;75:459
13. Deeg CA, Reese S, Gerhards H, Kaspers B. The uveitogenic potential of retinal S-antigen in horses. Invest Ophthalmol Vis Sci 2004;45(7):2286-92 (Pubitemid 38902600)
14. Adamus G, Amundson D. Epitope recognition of recoverin in cancer associated retinopathy: evidence for calcium-dependent conformational epitopes. J Neurosci Res 1996;45(6):863-72 (Pubitemid 26332574)
15. Grajewski RS, Silver PB, Agarwal RK, et al. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med 2006;203(4):851-6
16. Broekhuyse RM, Kuhlmann ED. Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. Invest Ophthalmol Vis Sci 1993;34(3):698-700 (Pubitemid 23095226)
17. Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002;69(1):12-18 (Pubitemid 34123340)
18. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment. Response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306(21):2340-7
19. Liu J, Wang L, Zhan S, et al. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2010(6):CD008127
20. Sheridan JP, Zhang Y, Riester K, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011;17(12):1441-8
21. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother 2002;36(7-8):1204-9 (Pubitemid 34755799)
22. Hussar DA. New drugs of 2003. J Am Pharm Assoc 2004;44(2):168-206
23. Elices MJ. Natalizumab. Elan/Biogen. Curr Opin Investig Drugs 2003;4(11):1354-62
24. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983;62:873-82 (Pubitemid 13008678)
25. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7 (Pubitemid 18091075)
26. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebocontrolled and double-blind study. Arch Dermatol 2002;138:467-71 (Pubitemid 34290024)
27. Tsambaos D, Eichelberg D, Goos M. Behcets syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278(4):335-6 (Pubitemid 16096033)
28. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61
29. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9 (Pubitemid 46586530)
30. Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcets disease. Arthritis Rheum 2010;62:2796-805
31. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcets disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31 (Pubitemid 36399030)
32. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcets disease. Ocul Immunol Inflamm 2000;8:293-301 (Pubitemid 32174750)
33. Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011;129(3):288-94
34. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegeners granulomatosis. Eye 2005;19:1017-18 (Pubitemid 43114989)
35. Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66 (Pubitemid 41702786)
36. Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005;89:1254-7 (Pubitemid 41638860)
37. Horie Y, Kitaichi N, Takemoto Y, et al. Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease. Mol Vis 2007;13:2334-8
38. Chebil A, Kort F, Bouraoui R, et al. Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection. J Fr Ophtalmol 2010;33(3):185-8
39. Lim JH, Lee YN, Kim YS, et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol 2011
40. Deuter CM, Koetter I, Guenaydin I, et al. Interferon alpha-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26:786-91 (Pubitemid 44386101)
41. Touitou V, Sene D, Fardeau C, et al. Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int Ophthalmol 2007;27(2-3):211-15
42. Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFN-alpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-46 (Pubitemid 34615979)
43. Vo AA, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006;1:844-52
44. Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9
45. Blum M, Andrassy K, Adler D, et al. Early experience with intravenous immunoglobulin treatment in Wegeners granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997;235:599-602 (Pubitemid 27445367)
46. LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8:49-57 (Pubitemid 30603998)
47. Rosenbaum JT, George Retinochoroidopathy RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999;127:545-9 (Pubitemid 29215765)
48. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcets disease. Br J Ophthalmol 2001;85:1287-8 (Pubitemid 33016103)
49. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002;102:59-67 (Pubitemid 34095225)
50. Gonzalez-Delgado M, Gonzalez C, Blazquez JI, et al. Intravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndrome. Neurologia 2004;19:401-3 (Pubitemid 39329309)
51. Aharon A, Zandman-Goddard G, Schoenfeld Y. Autoimmune multiorgan involvement in elderly men is it SLE? Clin Rheumatol 1994;13:631-4
52. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006;34:365-74 (Pubitemid 44137557)
53. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9 (Pubitemid 34620190)
54. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumor necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004;20:155-7 (Pubitemid 38197315)
55. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751-6
56. Bathon JM, Martin RW, Fleiscmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93 (Pubitemid 32162981)
57. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50 (Pubitemid 34620189)
58. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86 (Pubitemid 29135800)
59. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9 (Pubitemid 29063266)
60. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6 (Pubitemid 37409337)
61. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2262-72
62. Koizumi K, Poulaki V, Doehmen S, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 2003;44:2184-91 (Pubitemid 36520316)
63. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcets disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105 (Pubitemid 40092599)
64. Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcets disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41:61-70
65. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23 (Pubitemid 40216347)
66. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23 (Pubitemid 44838928)
67. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-7 (Pubitemid 41140552)
68. Heiligenhaus A, Horneff G, Greiner K, et al. Inhibitors of tumor necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd 2007;224:526-31 (Pubitemid 47099540)
69. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413 (Pubitemid 46624278)
70. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50 (Pubitemid 46580481)
71. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapses of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40 (Pubitemid 36427629)
72. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9 (Pubitemid 30151920)
73. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8 (Pubitemid 35453523)
74. Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. Sauders; Philadelphia: 2002. p. 177-214
75. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10
76. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9 (Pubitemid 34621118)
77. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohns disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20 (Pubitemid 39335798)
78. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7 (Pubitemid 32539117)
79. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76 (Pubitemid 41770166)
80. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91 (Pubitemid 40216323)
81. Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci 2007;48:3246-52 (Pubitemid 351261170)
82. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12 (Pubitemid 41057986)
83. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000;95:2395-6
84. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcets disease. Int Ophthalmol 2005;26:83-92 (Pubitemid 44781873)
85. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcets disease. Jpn J Ophthalmol 2007;51:191-6 (Pubitemid 46889493)
86. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005;19:841-5 (Pubitemid 41195135)
87. Lindstedt EW, Baarsma GS, Kuijpers RW, Van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthlmol 2005;89:533-6 (Pubitemid 40569703)
88. Merino G, Varas G, Diaz G, et al. Effectiveness of infliximab in patients with Behcet syndrome and severe uveoretinitis. Report of five cases. Rev Med Chil 2006;134:875-82 (Pubitemid 44357844)
89. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcets disease: a 24-month follow-up study. Rheumatology 2007;46:1161-4 (Pubitemid 47050622)
90. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcets disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8 (Pubitemid 38879203)
91. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcets disease. Ann Intern Med 2004;140:404-6 (Pubitemid 38268925)
92. Tongon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcets uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007;1110:474-84 (Pubitemid 350043037)
93. Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behcets disease. Invest Ophthalmol Vis Sci 2011;52:476-84
94. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcets disease: an open-label trial. Arthritis Rheum 2005;52:2478-84 (Pubitemid 41117435)
95. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6 (Pubitemid 38183244)
96. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6 (Pubitemid 351339402)
97. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sightthreatening panuveitis in Behcets disease. Lancet 2001;358:295-6 (Pubitemid 32738970)
98. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factoralpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50 (Pubitemid 46774863)
99. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-4 (Pubitemid 47492870)
100. Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9 (Pubitemid 44283053)
101. Adan A, Sanmarti R, Bures A, Casaroli-Marano RP. Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome. Am J Ophthalmol 2007;143:533-4
102. Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcets disease. Rheumatol Int 2005;25:1-5
103. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71 (Pubitemid 40775543)
104. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53 (Pubitemid 36842488)
105. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-4
106. Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 2008;47:1510-14
107. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010;30:1530-5
108. Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol 2011;129:250-2
109. Ito T, Sonoda KH, Hijioka K, et al. Acquired resistance to infliximab against uveitis due to Behcets disease after one year of administration. Jpn J Ophthalmol 2010;54:502-4
110. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16 (Pubitemid 38530193)
111. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum 2005;52:3279-89 (Pubitemid 41447111)
112. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46 (Pubitemid 44051069)
113. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
114. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007;132:52-65 (Pubitemid 46108762)
115. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91(3):319-24 (Pubitemid 46586527)
116. Calvo J, Campos C, Rueda Cid A, et al. Efficacy of adalimumab in Behcets disease. Description of 6 cases. Reumatol Clin 2011;7:258-61
117. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcets disease. Eye 2007;21:824-5 (Pubitemid 46909189)
118. Diaz Llopi M, Amselem L, Romero FJ, et al. Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 2007;82:131-2
119. Rudwaleit M, Rdevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with acute ankylosing spondylitis: result of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
120. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm 2010;18(3):226-32
121. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5 (Pubitemid 44468085)
122. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63:612-18
123. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-41 (Pubitemid 40946062)
124. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204 (Pubitemid 29009378)
125. Cohen SB, Woolley JM, Chan W, et al. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225-31 (Pubitemid 36152581)
126. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24 (Pubitemid 34214243)
127. Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007;91:263-4 (Pubitemid 46202883)
128. Lim WK, Fujimoto C, Ursea R, et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005;123:957-63 (Pubitemid 41057994)
129. Terrada C, Neven B, Boddaert N, et al. Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophthalmic Inflamm Infect 2011;1:133-6
130. El-Shabrawi YG, Christen WG, Foster SC. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res 2000;20:211-14 (Pubitemid 30209653)
131. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5 (Pubitemid 28041863)
132. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999;96:7462-6 (Pubitemid 29299684)
133. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-70 (Pubitemid 40631493)
134. Hernandez Garfella ML, Diaz Llopis M, Salom Alonso D, Cervera Taulet E. Recurrent uveitis and therapy with monoclonal antibody (daclizumab). Arch Soc Esp Oftalmol 2004;79:593-8
135. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21:283-93 (Pubitemid 37410117)
136. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;11:786-9 (Pubitemid 36520080)
137. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126:186-91 (Pubitemid 351240847)
138. Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009;247:687-92
139. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/ DrugShortages/UCM194907.pdf
140. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33 (Pubitemid 28363048)
141. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806 (Pubitemid 44497758)
142. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8 (Pubitemid 40129256)
143. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegeners granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89:1542 (Pubitemid 41527407)
144. Chauhan S, Kamal A, Thompson RN, et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009;93:984-5
145. Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010;18:223-5
146. Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011;50:1390-4
147. Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegeners granulomatosis. Br J Ophthalmol 2007;91:1414 (Pubitemid 47492887)
148. Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-6 (Pubitemid 46975985)
149. Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 2007;6:1-2
150. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-8 (Pubitemid 34547110)
151. Matteucci P, Magni M, Di Nicola M, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002;100:1104-5 (Pubitemid 34832655)
152. Whitcup SM, DeBarge LR, Caspi RR, et al. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 1993;67:143-50 (Pubitemid 23144450)
153. La Heij Kuijpers RW, Baarsma SG, et al. Adhesion molecules in iris biopsy specimens from patients with uveitis. Br J Ophthalmol 1998;82:432-7 (Pubitemid 28177158)
154. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13 (Pubitemid 37448923)
155. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80 (Pubitemid 37548113)
156. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:614-24
157. Gottlieb AB, Krueger JG, Bright R, et al. Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35 (Pubitemid 30470349)
158. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cellmediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600
159. Uchio E, Kijima M, Tanaka S, Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci 1994;35:2626-31 (Pubitemid 24137061)
160. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209 (Pubitemid 43379619)
161. Wang J, Ibrahim M, Turkcuoglu P, et al. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm 2010;18:395-8
162. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9 (Pubitemid 30251643)
163. Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcets disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-44 (Pubitemid 37508929)
164. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
165. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J 2009;16:77-81
166. Parrish C, Sobera J, Robbins C, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006;5:339-40
167. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71 (Pubitemid 41117408)
168. Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:297-300
169. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-2 (Pubitemid 40269746)
170. Lim LL, Fraunfelder FW, Rosenbaum J. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52 (Pubitemid 47585419)
171. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14 (Pubitemid 46349778)
172. Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66 (Pubitemid 41702786)
173. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sightthreatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91(3):335-9 (Pubitemid 46586530)